Mahwah, NJ, May 18, 2004 - Phillip
C. Thomas, Chief Executive Officer of DOBI Medical International, Inc.
(OTCBB:DBMI) will give a presentation at the MilanoTECH 2004 technology
conference in Milan, Italy. He will be accompanied by Angelo Secci, MD,
DOBI Medicals Vice President, Clinical Research, a clinical scientist
with an in-depth background in medical imaging and clinical research.
The DOBI Medical International presentation will include an overview of
the Company as well as a review of the Companys new medical technology
which is focused on the detection of angiogenesis, the excess vascularization
often associated with tumors. The MilanoTECH Conference will be held in
Milan, Italy at the Jolly Hotel Presidente on May 19 20, 2004.
DOBI Medical will be the opening presentation of the conference on May
19 at 9:20 local time.
DOBI Medical has completed 4 of 5 modules of its premarket
application process for final FDA acceptance of its noninvasive
ComfortScan system which is designed to inexpensively and painlessly
image new blood vessels that often support and sustain breast cancer.
The Company currently expects to submit its fifth and final PMA module
to the FDA in the second half of 2005. The ComfortScan system is currently
investigational and not yet for sale in the United States. International
sales of the ComfortScan system are expected to commence in Q4 of this
year. Earlier this month, DOBI Medical announced that it had received
renewal of its CE Mark Certification that will allow the shipment of its
ComfortScan system to European Union Countries and other countries where
the CE Mark certification is recognized.
About DOBI Medical International, Inc.
DOBI Medical is a development stage medical imaging company working to
create a new means for the improved diagnosis of cancer through the detection
of abnormal vascularization ("angiogenesis") associated with
tumors. DOBI Medicals first application of the technology is the
ComfortScan system, a non-invasive, non-ionizing, and pain-free dynamic
optical imaging system designed to assist physicians in the detection
and management of breast cancer. The ComfortScan system is intended to
achieve this by providing new, physiology-based imagery of abnormal vascularization
in the breast that are not readily available today.
buy xanax excellent description of the drugs
CAUTIONARY STATEMENT PURSUANT TO SAFE
HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements contained in this press release may contain information that
includes or is based upon certain forward-looking statements
within the meaning of the Securities Litigation Reform Act 1995 relating
to the business of DOBI Medical. These forward-looking statements represent
managements current judgment and assumptions and can be identified
by the fact that they do not relate strictly to historical or current
facts. Forward-looking statements are frequently accompanied by the use
of such words as anticipate, plans, believes,
expects, project, intends, or similar
expressions. Such forward looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to our ability
to secure additional financing; success of product development efforts;
our ability to timely meet federal, local and foreign government and industry
regulations and standards; timely and successful completion of our patient
clinical trials and submission of our premarket approval application to
the FDA; final approval of our ComfortScan system by the FDA; delays in
the manufacturing process caused by our inabilities or the inabilities
of our subcontractors to timely meet our specifications; our ability to
establish international and domestic distribution networks, our ability
to timely export our products to international markets; acceptance and
use of our ComfortScan system by physicians, imaging clinics, and patients;
our ability to obtain third party payer reimbursement; and our ability
to compete on price and quality. Any one of these or other risks and uncertainties
may cause actual results to be materially different from those described
herein or elsewhere by us. Certain of these risks and uncertainties are
or will be described in greater detail in our filings from time to time
with the Securities and Exchange Commission, which we strongly urge you
to read, including our 2003 Annual Report on Form 10-KSB filed on February
18, 2004. Subsequent written and oral forward looking statements attributable
to us or to persons acting on our behalf are expressly qualified in their
entirety by the cautionary statements and risk factors set forth above
and elsewhere in our reports filed with the Securities and Exchange Commission.
We expressly disclaim any intent or obligation to update any forward looking